| Revision as of 01:02, 6 January 2025 edit71.105.192.120 (talk) -- Draft creation using the WP:Article wizard --Tag: Visual edit | Revision as of 02:15, 6 January 2025 edit undo71.105.192.120 (talk) everythingTag: Visual editNext edit → | ||
| Line 1: | Line 1: | ||
| Shlomi Raz is a key figure in the field of psychedelic research, particularly known for his work at Eleusis, a company he founded to explore the therapeutic potential of psychedelics. His journey from a successful career in finance to the world of psychedelic medicine highlights his deep interest in psychology and the potential to address significant unmet medical needs. | |||
| {{AfC submission|t||ts=20250106010216|u=71.105.192.120|ns=118|demo=}}<!-- Important, do not remove this line before article has been created. --> | |||
| === Career Background === | |||
| Before his involvement with Eleusis, Raz had a prominent career in the financial sector. He worked as a Managing Director at Goldman Sachs and was also part of JPMorgan earlier in his career. This background in high-stakes finance gave him the expertise to navigate complex business environments, which he later applied to the startup world of psychedelic medicine. | |||
| Shlomi holds a Bachelor of Science in Finance from Georgetown University, as well as a Master of Arts from New York University. These academic credentials provided a foundation for his transition into the business world, where he honed his leadership skills and financial acumen. | |||
| === Transition to Psychedelic Medicine === | |||
| Raz's decision to pivot from finance to psychedelic research was influenced by his personal interest in psychology and the profound potential of psychedelics as therapeutic agents. He founded Eleusis in 2013 with the vision of developing psychedelics into medically approved treatments. Eleusis is dedicated to leveraging the unique properties of psychedelics, such as anti-inflammatory and neurogenic effects, to develop treatments for various conditions like Alzheimer's disease and mental health disorders. | |||
| His work at Eleusis is aimed at pushing the boundaries of psychedelic science and bringing much-needed innovation to the healthcare industry, particularly for conditions where current treatments are insufficient. Eleusis stands at the forefront of psychedelic medicine, seeking to harness compounds like psilocybin and MDMA to address conditions ranging from depression to neurodegenerative diseases. | |||
| === Business Strategy and Growth === | |||
| Under Shlomi Raz’s leadership, Eleusis has gained significant attention. In 2022, the company made headlines with its plans to go public through a merger with Silver Spike Acquisition Corp. II, a special purpose acquisition company (SPAC). This move was part of a broader trend in the psychedelic sector, where companies have begun to attract attention from investors seeking to capitalize on the growing acceptance of psychedelic research for medical purposes. | |||
| Eleusis also stands out because it aims to approach psychedelic medicine from a scientific, data-driven perspective. By focusing on clinical trials and research to establish safety and efficacy, the company hopes to push the FDA and other regulatory bodies to approve psychedelic therapies for a wide range of conditions. | |||
| === Vision for the Future === | |||
| Shlomi Raz’s vision for the future of psychedelic medicine revolves around breaking the stigma associated with psychedelics and integrating them into the mainstream healthcare system. Through his work, he hopes to provide innovative, effective treatments for individuals suffering from conditions like depression, anxiety, and Alzheimer's. His passion for improving mental health through non-traditional means has driven Eleusis’ ambitious research agenda. | |||
| The company is also interested in the broader societal implications of psychedelic therapies, including their potential to shift how we understand consciousness, mental health, and emotional well-being. | |||
| === Eleusis' Research Focus === | |||
| Eleusis conducts research into several areas: | |||
| * '''Neuroinflammation:''' A key area of focus is how psychedelics can influence neuroinflammation, a major factor in diseases like Alzheimer's and other neurodegenerative conditions. Research suggests that psychedelics could have a unique ability to reduce inflammation in the brain, offering a novel therapeutic avenue. | |||
| * '''Mental Health:''' Eleusis is also exploring the potential of psychedelics in treating mental health conditions, such as depression, anxiety, and PTSD. These disorders have shown promise as areas where psychedelics, particularly psilocybin and MDMA, could be transformative. | |||
| * '''Psychedelic-Assisted Psychotherapy:''' Eleusis aims to combine psychedelic compounds with psychotherapy to provide a comprehensive approach to treating psychiatric disorders. This model has already shown success in research conducted by other organizations, including the Multidisciplinary Association for Psychedelic Studies (MAPS). | |||
| === Legacy and Impact === | |||
| Shlomi Raz’s impact on the psychedelic space continues to evolve as more research emerges, and as the stigma around psychedelic substances continues to decrease. By combining his expertise in business and finance with his passion for therapeutic innovation, Raz has positioned himself as a leader in the field, advocating for a future where psychedelics are a recognized and widely used part of the medical toolkit. | |||
| His story also highlights a growing trend of professionals from diverse industries, such as finance, moving into the psychedelic space driven by a combination of personal interest and a desire to contribute to a significant societal transformation. | |||
| Through Eleusis and his work, Raz hopes to create lasting change in the field of medicine, offering hope to individuals suffering from mental health disorders and chronic diseases.<!-- Important, do not remove this line before article has been created. --> | |||
| Line 9: | Line 43: | ||
| == References == | == References == | ||
| <!-- Inline citations added to your article will automatically display here. See en.wikipedia.org/WP:REFB for instructions on how to add citations. --> | <!-- Inline citations added to your article will automatically display here. See en.wikipedia.org/WP:REFB for instructions on how to add citations. --> | ||
| {{reflist}} | |||
| {{reflist}} | |||
| https://in.marketscreener.com/insider/SHLOMI-RAZ-A2A6KJ/ | |||
| https://blossomanalysis.com/people/shlomi-raz/ | |||
Revision as of 02:15, 6 January 2025
Shlomi Raz is a key figure in the field of psychedelic research, particularly known for his work at Eleusis, a company he founded to explore the therapeutic potential of psychedelics. His journey from a successful career in finance to the world of psychedelic medicine highlights his deep interest in psychology and the potential to address significant unmet medical needs.
Career Background
Before his involvement with Eleusis, Raz had a prominent career in the financial sector. He worked as a Managing Director at Goldman Sachs and was also part of JPMorgan earlier in his career. This background in high-stakes finance gave him the expertise to navigate complex business environments, which he later applied to the startup world of psychedelic medicine.
Shlomi holds a Bachelor of Science in Finance from Georgetown University, as well as a Master of Arts from New York University. These academic credentials provided a foundation for his transition into the business world, where he honed his leadership skills and financial acumen.
Transition to Psychedelic Medicine
Raz's decision to pivot from finance to psychedelic research was influenced by his personal interest in psychology and the profound potential of psychedelics as therapeutic agents. He founded Eleusis in 2013 with the vision of developing psychedelics into medically approved treatments. Eleusis is dedicated to leveraging the unique properties of psychedelics, such as anti-inflammatory and neurogenic effects, to develop treatments for various conditions like Alzheimer's disease and mental health disorders.
His work at Eleusis is aimed at pushing the boundaries of psychedelic science and bringing much-needed innovation to the healthcare industry, particularly for conditions where current treatments are insufficient. Eleusis stands at the forefront of psychedelic medicine, seeking to harness compounds like psilocybin and MDMA to address conditions ranging from depression to neurodegenerative diseases.
Business Strategy and Growth
Under Shlomi Raz’s leadership, Eleusis has gained significant attention. In 2022, the company made headlines with its plans to go public through a merger with Silver Spike Acquisition Corp. II, a special purpose acquisition company (SPAC). This move was part of a broader trend in the psychedelic sector, where companies have begun to attract attention from investors seeking to capitalize on the growing acceptance of psychedelic research for medical purposes.
Eleusis also stands out because it aims to approach psychedelic medicine from a scientific, data-driven perspective. By focusing on clinical trials and research to establish safety and efficacy, the company hopes to push the FDA and other regulatory bodies to approve psychedelic therapies for a wide range of conditions.
Vision for the Future
Shlomi Raz’s vision for the future of psychedelic medicine revolves around breaking the stigma associated with psychedelics and integrating them into the mainstream healthcare system. Through his work, he hopes to provide innovative, effective treatments for individuals suffering from conditions like depression, anxiety, and Alzheimer's. His passion for improving mental health through non-traditional means has driven Eleusis’ ambitious research agenda.
The company is also interested in the broader societal implications of psychedelic therapies, including their potential to shift how we understand consciousness, mental health, and emotional well-being.
Eleusis' Research Focus
Eleusis conducts research into several areas:
- Neuroinflammation: A key area of focus is how psychedelics can influence neuroinflammation, a major factor in diseases like Alzheimer's and other neurodegenerative conditions. Research suggests that psychedelics could have a unique ability to reduce inflammation in the brain, offering a novel therapeutic avenue.
- Mental Health: Eleusis is also exploring the potential of psychedelics in treating mental health conditions, such as depression, anxiety, and PTSD. These disorders have shown promise as areas where psychedelics, particularly psilocybin and MDMA, could be transformative.
- Psychedelic-Assisted Psychotherapy: Eleusis aims to combine psychedelic compounds with psychotherapy to provide a comprehensive approach to treating psychiatric disorders. This model has already shown success in research conducted by other organizations, including the Multidisciplinary Association for Psychedelic Studies (MAPS).
Legacy and Impact
Shlomi Raz’s impact on the psychedelic space continues to evolve as more research emerges, and as the stigma around psychedelic substances continues to decrease. By combining his expertise in business and finance with his passion for therapeutic innovation, Raz has positioned himself as a leader in the field, advocating for a future where psychedelics are a recognized and widely used part of the medical toolkit.
His story also highlights a growing trend of professionals from diverse industries, such as finance, moving into the psychedelic space driven by a combination of personal interest and a desire to contribute to a significant societal transformation.
Through Eleusis and his work, Raz hopes to create lasting change in the field of medicine, offering hope to individuals suffering from mental health disorders and chronic diseases.
References
https://psychedelicreview.com/person/shlomi-raz/